Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
 |
- Acquisition supportsServier'sstrategicambition in rare neurologywithsevasemten, alate-stageinvestigationaltreatment forBecker and Duchennemusculardystrophies.
- TheacquiredassetandexpertteamstrengthenServier'scommitmentto innovate for patients with high unmet medical needs.
SURESNES, France, July 13, 2026 /PRNewswire/ --Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX),forup to$2.65 billion,including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.
Theacquisitionsignificantly advances Servier'srareneurologypipeline with a late-stage asset,sevasemten,currently being investigated in a pivotal cohort in Becker muscular dystrophy(BMD), and in phase 2 in Duchenne muscular dystrophy(DMD). It also provides Servier with additional capabilities by integrating Edgewise Therapeutics' expertise to advance the development of sevasemten.
Sevasemten is an orally administered potential first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy.BMDis arare,X-linkedgenetic disorder that causes progressive muscle loss, withcurrently no approved treatment for patients.Theloss ofmusclefunctionis irreversible and impacts patients' abilities to perform everyday activities like walking.DMDis amoresevere, recessiveX-linkedgenetic, degenerative muscle disorder beginning at birth that causes patients to lose their walking ability by their early teens. It is the most common type of muscular dystrophy with a median life expectancy of around30 years.
"Delivering precision therapies to people withrareand devastating conditions is at the heart of Servier's mission.The combination ofEdgewise'sexpertisein muscular dystrophywithServier'sglobalcapabilitiesis a major step forwardtoaccelerate the development ofinnovative treatmentsforpeopleliving with Becker and Duchenne",saidOlivier Laureau, President of Servier. "This acquisition is a strategic milestone in achievingour Servier 2030 ambitionin rare neurology."
"Servier'sstrongcommitment to patients, growing focusonrareneurology, and established global capabilities position them as the optimal partner to advancethemuscular dystrophybusiness",saidKevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics.
Contacts
Servier Group, Olympe Muller
olympe.muller@servier.com
